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Plasmodium falciparum merozoite surface 
antigen-specific cytophilic IgG and control 
of malaria infection in a Beninese birth cohort
Rafiou Adamou1,2,3*† , Célia Dechavanne1†, Ibrahim Sadissou1,2,4,5, Tania d’Almeida1, Aziz Bouraima2, 
Paulin Sonon2,4,5, Roukiyath Amoussa2, Gilles Cottrell1, Agnès Le Port1, Michael Theisen6,7,8, 
Edmond J. Remarque9, Shirley Longacre10, Kabirou Moutairou4, Achille Massougbodji2, Adrian J. F. Luty1,2, 
Gregory Nuel11, Florence Migot‑Nabias1, Ambaliou Sanni3, André Garcia1,2, Jacqueline Milet1 
and David Courtin1
Abstract 
Background: Substantial evidence indicates that cytophilic IgG responses to Plasmodium falciparum merozoite 
antigens play a role in protection from malaria. The specific targets mediating immunity remain unclear. Evaluat‑
ing antibody responses in infants naturally‑exposed to malaria will allow to better understand the establishment of 
anti‑malarial immunity and to contribute to a vaccine development by identifying the most appropriate merozoite 
candidate antigens.
Methods: The study was based on parasitological and clinical active follow‑up of infants from birth to 18 months of 
age conducted in the Tori Bossito area of southern Benin. For 399 infants, plasma levels of cytophilic IgG antibodies 
with specificity for five asexual stage malaria vaccine candidate antigens were determined by ELISA in infants’ periph‑
eral blood at 6, 9, 12 and 15 months of age. Multivariate mixed logistic model was used to investigate the association 
between antibody levels and anti‑malarial protection in the trimester following the IgG quantification. Moreover, the 
concentrations of merozoite antigen‑specific IgG were compared between a group of infants apparently able to con‑
trol asymptomatic malaria infection (CAIG) and a group of infants with no control of malaria infection (Control group 
(NCIG)). Protective effect of antibodies was also assessed after 15 months of malaria exposure with a Cox regression 
model adjusted on environmental risk.
Results: Cytophilic IgG responses to AMA1, MSP1, MSP2‑3D7, MSP2‑FC27, MSP3 and GLURP R2 were associated with 
increasing malarial infection risk in univariate analysis. The multivariate mixed model showed that IgG1 and IgG3 to 
AMA1 were associated with an increased risk of malarial infection. However infants from CAIG (n = 53) had signifi‑
cantly higher AMA1‑, MSP2‑FC27‑, MSP3‑specific IgG1 and AMA1‑, MSP1‑, MSP2‑FC27‑, MSP3 and GLURP‑R2‑specific 
IgG3 than those from NCIG (n = 183). The latter IgG responses were not associated with protection against clinical 
malaria in the whole cohort when protective effect is assessed after 15 months of malaria exposition.
Conclusion: In this cohort, merozoite antigen‑specific cytophilic IgG levels represent a marker of malaria exposure in 
infants from 6 to 18 months of age. However, infants with resolution of asymptomatic infection (CAIG) seem to have 
acquired naturally immunity against P. falciparum. This observation is encouraging in the context of the development 
of multitarget P. falciparum vaccines.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Background
Plasmodium falciparum malaria remains a significant 
cause of infant mortality and morbidity in many parts 
of the world especially in sub-Saharan Africa. In 2017, 
there were an estimated 219 million cases of malaria and 
435,000 deaths [1]. In endemic countries, children under 
5  years are particularly vulnerable to malaria. During 
repeated exposure to infected Anopheles bites, infants 
develop immune responses that reduce clinical symp-
toms and life-threatening complications. Antibodies are 
known to be key components of naturally-acquired anti-
malarial [2] most notably in studies involving passive 
transfer of antibodies from immune adults to malaria-
infected children that resulted in reductions of both 
parasitaemia and clinical symptoms [2, 3]. Among IgG 
subclasses, cytophilic IgG1 and IgG3 are thought to play 
a key role in anti-malarial protection [4, 5]. However, it 
is unclear which merozoite antigens may be the most 
important targets of naturally-acquired immunity [6].
An efficacious blood stage vaccine against malaria that 
remains potent in different transmission settings would 
greatly contribute to reducing the disease burden among 
endemic populations. RTS,S/AS01  (Mosquirix®) is the 
most advanced malaria vaccine, targeting pre-erythro-
cytic stages, but it is suboptimal both in terms of efficacy 
and duration [7, 8]. Developing new and more potent 
malaria vaccines is, therefore, a priority and sero-epi-
demiological studies are one of the most valuable tools 
that can be used to identify naturally-acquired protective 
anti-malarial antibody (Ab) responses.
To date, a number of P.  falciparum merozoite anti-
gens have been assessed in human vaccine trials includ-
ing the most studied antigens: merozoite surface protein 
(MSP) 1, 2, 3, apical membrane antigen 1 (AMA1) and 
glutamate rich protein (GLURP) [6]. Numerous antibody 
responses targeting P. falciparum merozoite surface pro-
teins have been associated with reduced risk of malaria 
and high parasitaemia in naturally-exposed children or 
adults [9–19]. However a number of immuno-epide-
miological studies conducted in endemic communities 
have provided conflicting data, with antibody responses 
to the same antigens appearing to be protective against 
malaria in some studies but associated with a higher risk 
of malaria in others [13, 17, 20–32]. The reasons for dis-
cordant observations could be numerous and most likely 
include specific differences in malaria transmission pat-
terns (unstable, stable), study design (active or passive 
follow-up), population under study (infants, children, 
adults, host genetic diversity) and technical aspects 
(differences in operating procedure and methods of data 
analysis). The study of antibody responses to merozoite 
candidate vaccine antigens in infant cohorts are of inter-
est as young children are the main victims of P.  falcipa-
rum and they represent the main target in any malaria 
vaccination strategy. Previous work conducted in the 
Tori-Bossito cohort showed that factors such as age, past 
and current malaria infections, malaria antibody lev-
els at birth, as well as exposure to Anopheles bites were 
significantly associated with the natural acquisition of 
anti-malarial IgG1 and IgG3 responses in 6- to 18-month 
old infants [33]. In the same cohort, the present study 
aimed to investigate the role of the cytophilic antibody 
responses acquired against specific P.  falciparum can-
didate vaccine antigens in protection of infants against 
P.  falciparum infection. IgG1 and IgG3 responses to five 
leading P.  falciparum merozoite-stage vaccine candidate 
antigens (AMA1, MSP1, MSP2, MSP3, and GLURP) were 
quantified to investigate associations between these anti-
body responses and anti-malarial protection from 6 to 
18 months of age.
Methods
Study design
The data here were collected from a longitudinal malaria 
cohort study conducted in 9 villages of the district of Tori 
Bossito located in the Southern part of Benin described 
in detail elsewhere [34]. Briefly, 656 newborns were 
enrolled between June 2007 and January 2010 and both 
clinical and parasitological follow-ups were performed 
from birth to 18 months of age. Mothers were invited to 
bring their infants to the health centre at any time in case 
of suspicious fever or clinical signs, whether related to 
malaria or not. In case of fever, a questionnaire and both 
a rapid diagnostic test (RDT) and a thick blood smear 
(TBS) were performed. Symptomatic malaria infection 
(fever or history of fever in the preceding 48 h and posi-
tive TBS and/or RDT) was treated with the artemether–
lumefantrine combination, as recommended by the 
National Malaria Control Programme. The same pro-
cedure was applied for each child who was visited every 
week by a nurse of the programme during the entire 
follow-up. Moreover a systematic TBS was performed 
monthly to detect malaria infection.
During systematic visits P. falciparum infection could 
be symptomatic or asymptomatic (absence of fever or 
history of fever in the preceding 48 h, presence of P. falci-
parum and absence of symptomatic infections in the fol-
lowing 3 days). All blood smears were stained with 10% 
Keywords: Plasmodium falciparum, Malaria, Cytophilic IgG, Merozoite vaccine candidate antigens
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Giemsa and were read by two independent technicians. 
A third reading was performed when discordant cases 
occurred.
For each woman at delivery, a questionnaire collect-
ing information on maternal age, parity, use of Intermit-
tent Preventive Treatment during pregnancy (IPTp) and 
bed net possession was administered. In addition, thick 
and thin placental smears were made to detect placen-
tal malaria. An entomological, nutritional and biologi-
cal follow-up was also performed as described in detail 
elsewhere [35]. During the study, the annual P.  falcipa-
rum entomological inoculation rate was calculated in 
all villages, giving an average of 15.5 infected Anopheles 
bites/person/year [35], with large spatial and temporal 
variations between the villages. A predictive regression 
model using entomological and environmental data was 
developed to predict the spatiotemporal variability of 
malaria transmission within the nine villages [35]. Hence, 
a time-dependent environmental risk of exposure (ERE) 
was attributed to each child included in the cohort. A 
questionnaire concerning nutrition was administered 
by supervisors to collect information about breastfeed-
ing and to assess the quality of feeding practices through 
a qualitative dietary 24  h recall. An individual dietary 
diversity score was created according to Food and Agri-
culture Organization recommendations [34, 36]. Also, a 
time-dependent quantitative variable accounting for the 
past 3-month feeding practices was created [34].
Infant blood samples were collected in EDTA vials 
every 3  months during the follow-up and plasmas were 
conserved at − 80 °C for antibody quantification. In the 
present study, the main objective was to assess the pro-
tective role of infant antibody responses to malaria infec-
tion every 3 months following the blood draw. Antibody 
measurements at 0 and 3  months of age were excluded 
because of the content in those samples of antibodies 
from mixed maternal and infant origins. Therefore, only 
antibody measurements at 6, 9, 12 and 15 months were 
processed.
Recombinant antigens
The plasmodial antigens used in this study included a 
recombinant AMA1 (amino-acids 25–545, FVO strain), 
which was expressed in Pichia pastoris and was produced 
by the Biomedical Primate Research Centre (Rijswijk, 
The Netherlands) [37].  MSP119 (Uganda-Palo-Alto 
strain) was expressed in a Baculovirus/insect cell system 
[38]. It is composed of 2 combined long peptides (amino 
acids 1–43 and 1615–1723) and was produced at Pasteur 
Institute of Paris. MSP2 (3D7 and FC27, whole proteins 
without the secretion signal and the GPI anchorage) 
were the gift of collaborators from La Trobe University 
(Melbourne, Australia) [39, 40]. GLURP-R0 (amino acids 
25–514, F32 strain), GLURP-R2 (amino acids 706–1178, 
F32 strain) and MSP3 (amino acids 212–380, F32 strain) 
were produced by the Infection-Immunity Department 
of the Statens Serum Institute of Copenhagen (Denmark) 
and were expressed in Escherichia coli.
Antibody measurements
The standard operating procedures developed by the 
African Malaria Network Trust was used to assess cyt-
ophilic IgG1 and IgG3 concentrations by enzyme linked 
immunosorbent assay (ELISA) to a panel of recombinant 
proteins, as described previously [13]. Briefly, recom-
binant proteins (0.1  µg/well) diluted in phosphate buff-
ered saline (PBS) were coated on MaxiSorp Nunc plates 
(Thermo Fisher Scientific, Denmark) and blocked with 
3% powdered-milk 0.1% PBS-Tween 20. Plasma samples 
were diluted 1:50 for all recombinant proteins. Peroxi-
dase conjugated anti-human IgG1 (NL16 clone) diluted 
1:2000 and anti-human IgG3 (ZG4 clone) diluted 1:5000 
(Skybio, France) were used for revealing the reaction 
with 3,3′,5,5′-tetramethylbenzidine (TMB) as substrate. 
Standard curves were established using human IgG1 and 
IgG3 purified proteins (Binding Site, France) to deter-
mine the concentration of specific antibodies. Each point 
was tested in duplicate.
Management of ELISA data
R script based on ADAMSEL software (Auditable Data 
Analysis and Management System for ELISA) [41] was 
used to transform optical density (OD) values into anti-
body concentrations. Discordant duplicates (with a 
variation coefficient > 15%) were retreated. OD that 
were below detection threshold or over saturation were 
referred to as “Low” and “High” concentration values (µg/
mL) respectively. A stochastic expectation maximization 
algorithm [42] already applied to ELISA analyses [43] was 
used to impute data in these particular cases taking into 
account the lowest, the highest and the standard concen-
tration values of the ELISA plates in which the Low/High 
OD values were recorded.
Analysis strategy
In the first approach, a logistic mixed model was per-
formed to study the association between the antibody 
levels quantified at 6, 9, 12 and 15  month of age for 
399 infants and the risk of malarial infection from 6 to 
18 month of age. Each quarterly antibody measurement 
was associated with the presence or absence of at least 
one malaria infection during the following 3  months in 
the logistic mixed model. To focus specifically on anti-
body-mediated effects, the cytophilic IgG levels were first 
adjusted using a linear regression on the nuisance varia-
bles (prematurity, parity, use of IPTp, bed net possession, 
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health centre and maternal age). The residuals of these 
adjustments were then used in the models. Moreover, 
all analyses were adjusted on maternal and newborn’s 
covariates known to potentially influence malarial infec-
tion: placental malaria, parity, prematurity, haemoglobin 
levels at delivery and birth, administration of IPTp, birth 
weight, ethnicity, age, environmental risk of exposure to 
malaria, gender, nutrition status, sickle cell trait and bed 
net use. Multivariate analysis was performed including 
the variables with p ≤ 0.10 in the univariate analysis.
In the second approach, a linear mixed model was 
used to assess the difference of the levels of cytophilic 
IgG between a group of infants apparently able to con-
trol asymptomatic malaria infections (CAIG (n = 53)) 
and a control group (NCIG (n = 183)) of infants infected 
by P.  falciparum without resolution of asymptomatic 
malaria infection. The control of asymptomatic infection 
was defined here as the disappearance of asymptomatic 
infections over time based on TBS examination. Infants 
from CAIG seem able to control not only the disease 
symptom (asymptomatic infection) but also the parasi-
taemia. NCIG was composed of infants at least exposed 
to two malaria infections during the follow-up. No differ-
ence in term of environmental risk of exposure to malaria 
(ERE variable) was observed between both groups. It is 
important to notice that the linear mixed model took into 
account IgG cytophilic levels at 6, 9, 12 and 15 months, 
respectively.
A linear mixed model was used to test the association 
between the antibody quantification at 15  months and 
the parasite density in the following quarter. The mean of 
the parasite density between 15 and 18 months (all infec-
tions combined) was calculated and antibody levels were 
divided into 4 categories according to the quartiles.
Finally, a Cox proportional hazards regression model 
was used to test the protective effect of IgG responses 
previously associated with the phenotype of asympto-
matic infection clearance (CAIG) at 15 months of age in 
the whole sample (CAIG + NCIG). Hazard ratios (HR) 
of clinical malaria were calculated on the 15–18 months 
period adjusted by ERE. To avoid a bias due to anti-
malarial therapy, it has been considered a 14 days period 
after treatment where the infants were not considered 
at risk. Thus for infants who had a symptomatic malaria 
infection at blood sampling (n = 14) or within the 2 weeks 
before blood sampling, the starting point of survival anal-
ysis was shift to 14  days after treatment (n = 28). Those 
with an asymptomatic infection at sampling (n = 19) were 
excluded from analysis.
All statistical analyses except Cox model were per-
formed using Stata, version 13.0 (StatCorp LP, TX, USA). 
Cox model were performed using the R package “sur-
vival” [44]. Statistical significance was set at p < 0.05.
Ethics
The study protocol was approved by the Ethics Com-
mittee of the University of Abomey-Calavi (Faculté 
des Sciences de la Santé) in Benin and the Consultative 
Committee of Ethics of the Institut de Recherche pour le 
Développement. All women signed an informed consent 
before enrollment (which also included their children). 
All the methods were carried out in accordance with the 
approved guidelines.
Results
Characteristics of study participants
Newborns for whom plasma samples and clinical and 
parasitological data were available were included in the 
analyses (n = 399). Eighty-two per cent of the mothers 
declared having received IPTp at least once (sulfadoxine–
pyrimethamine is the treatment recommended by the 
Beninese National Malaria Control Programme). Four-
teen per cent of them were primigravidae and 10% had 
an infected placenta at delivery. Eleven per cent of the 
newborns had a low birth weight (< 2500 g) and 12% were 
born prematurely. The sex ratio was 0.98 and infants fol-
lowed in the study belonged to different ethnic groups: 
Tori and Fon were the principal ethnicities represented 
with minorities of Aïzo and Yoruba. Sickle-cell trait 
(HbAS) carriers accounted for 22% of the study popula-
tion. Details of the study participants are presented in 
Table 1.
A total of 834 uncomplicated malaria attacks (UMA) 
(from 1 to 11 UMA/infant) and of 168 asymptomatic 
infections (from 1 to 8 asymptomatic infections/infant) 
were recorded during the follow-up. Based on the defi-
nition (cf. “Methods”), 53 infants were included in CAIG 
and 183 infants in NCIG (Table 2).
Anti‑malarial IgG levels according to the risk of malaria 
infection
In this analysis, the association between specific IgG lev-
els and protection to malaria was investigated. Univariate 
analyses showed that both IgG1 and IgG3 levels quanti-
fied at 6, 9, 12 and 15  months of age were significantly 
associated with increasing risk of malarial infection 
within the 3 months after blood draw (p < 0.05) with the 
exception of antibody responses to GLURP R0 (Table 3). 
Placental infection, ethnic group, environmental risk of 
exposure to malaria, nutritional status and age were also 
associated with malarial infection (p < 0.10). None of the 
other covariables showed an association with the risk of 
infection (Table 3).
Covariables associated with malarial infection (p < 0.10) 
in univariate analysis were included in the multivari-
ate analysis (Table  4). Given that a strong correlation 
exists between IgG1 and IgG3 responses, a top-down 
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Table 1 Characteristics of the participants
*Data on different variables are not available for all individuals
Individuals (n = 399) Variables* Characteristics (%; n)
Mothers Intermittent preventive treatment (n = 399) Yes: 82% (327)
No: 18% (72)
Gravidity status (n = 399) Primigravidity: 15% (58)
Multigravidity: 85% (341)
Placental malaria (n = 383) Yes: 10% (37)
No: 90% (346)
Infants Low birth weight (< 2500 g) (n = 399) Yes: 12% (46)
No: 88% (353)
Prematurity (n = 399) Yes: 11% (45)
No: 89% (354)
Gender (n = 399) Female: 50% (201)
Male: 50% (198)
Ethnicity (n = 390) Tori: 74% (289)
Fon: 10% (39)
Others: 16% (62)
Bed net possession (n = 399) Yes: 65% (258)
No: 35% (141)
HbAS (n = 381) Yes: 23% (87)
No: 77% (294)
Table 2 Clinical and parasitological characteristics for infants in CAIG and NCIG groups
a CAIG was composed by 53 infants with spontaneous clearance of at least one asymptomatic infection. Among these 53 infants, six never had febrile malaria during 
the follow-up while 47 also developed at least one malaria attack. Among the 168 asymptomatic infections, 88 and 80 respectively occurred in CAIG and NCIG during 
the whole follow-up. 64/88 were followed by a negative of thick blood smears in the time, 17/88 were followed by a malaria attacks and 7/88 occurred at the end of 
the follow-up for which it was not possible to determine the outcome. Concerning NCIG, 62/80 were followed by a malaria attacks and 18/80 occurred at the end of 
the follow-up for which it was not possible to determine the outcome
b Parasite density was expressed in number of Pf-infected red blood cells for 100 leucocytes
c The time expressed in days between the detection of asymptomatic infection and the occurrence of febrile malaria was higher in CAIG than NCIG. All infants (n = 30) 
with only one malaria infection were considered as not sufficiently exposed to belong to both groups and excluded
d Environmental risk of exposure to malaria was estimated for each infant once a month. No significant difference of exposure to malaria was observed between 
infants from CAIG and NCIG (p = 0.11; Mann–Whitney test)
Malaria infection  groupsa
Asymptomatic infection clearance 
without anti‑malarial treatment group (CAIG)
N = 53
Control group (NCIG)
N = 183
Infections during the follow‑up asymptomatic infections, no (%)
 No infection 0 121 (66)
 1 24 (45) 48 (26)
 2–3 29 (55) 13 (7)
 > 3 0 1 (0)
Symptomatic infections, no (%)
 No infection 6 (11) 0 (0)
 1 17 (32) 26 (14)
 2–3 18 (34) 102 (56)
 > 3 12 (23) 55 (30)
Parasite  densityb in asymptomatic infections, median (IQR) 38.6 (6.2–143.9) 60.2 (6.4–168.8)
Parasite density in symptomatic infections, median (IQR) 255.7 (8.0–806.8) 180.3 (10.1–698.8)
Time until malaria attacks (days)c, median (25th–75th) 34 (26–47) 13.5 (6–31)
Environmental risk of exposure to  malariad during the follow‑up, 
median (25th–75th)
3.06 (2.15–4.60) 3.89 (2.54–5.70)
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multivariate model was applied separately for both iso-
types. Environmental risk and age variables remained 
positively associated with the risk of malarial infection 
from 6 to 18  months of age. IgG1 and IgG3 to AMA1 
were associated with an increased risk of infection with 
P.  falciparum within the 3  months after blood draw 
(OR = 1.07; p = 0.039 and OR = 1.09; p = 0.021, respec-
tively) (Table 4).
Anti‑malarial IgG levels according to malaria 
symptomatology and parasitaemia
Individuals belonging to the CAIG group had higher 
antibody levels compared to those from the NCIG 
group. Thus, their levels of AMA1-, MSP2-FC27-, MSP3-
specific IgG1 and AMA1, MSP1, MSP2-FC27, MSP3, 
GLURP-R2-specific IgG3 were significantly higher 
(p ≤ 0.05), whilst their levels of IgG3 with specificity 
for MSP2-3D7 displayed trends towards higher levels 
(p = 0.067) (Table 5). Then, the assessment of the protec-
tive effect of Ab responses previously associated to CAIG 
in the whole cohort at 15 month of age have been done 
Table 3 Factors associated with  malarial infection from  6 
to  18  months of  age (univariate analysis with  logistic 
mixed model)
Significant p values (p ≤ 0.10) are mentioned in italics
OR: odds ratio; OR > 1: variables associated with higher risk of malarial infection 
from 6 to 18 months of age, OR < 1: variables associated with lower risk of 
malarial infection from 6 to 18 months of age, p: p-value, CI: confidence interval
*Tori, Fon and other less represented ethnic groups (Aïzo, Yoruba) were present 
in the study area: Tori were used as the reference group in the analysis. In the 
present analysis, the level of IgG1 and IgG3 quantified at each plasma collection 
(6, 9, 12 and 15 month of age) was correlated with malarial infection in the 
following trimester. Similar results were obtained when analysis was performed 
using data for symptomatic infections only
Variables OR p CI 95%
Placental malaria 1.91 0.023 [1.09,3.34]
Multigravida 0.85 0.521 [0.52,1.38]
Prematurity 0.86 0.611 [0.50,1.50]
Maternal Hb level at delivery 0.94 0.347 [0.83,1.06]
IPTp intake 0.84 0.443 [0.53,1.31]
Ethnic groups*
 Fon 1.08 0.789 [0.60,1.95]
 Others 0.53 0.016 [0.32,0.89]
Low birth weight 0.87 0.637 [0.51,1.50]
Environmental risk 1.21 < 0.001 [1.16,1.27]
Female 1.22 0.251 [0.86,1.72]
Infant Hb level at birth 0.99 0.883 [0.91,1.08]
Nutritional status 1.59 0.056 [0.98,2.58]
HbAS 0.94 0.802 [0.62,1.44]
Bed net possession 0.76 0.138 [0.53,1.09]
Age (6 month at reference)
 9 1.90 0.001 [1.29,2.80]
 12 4.58 < 0.001 [3.11,6.75]
 15 6.04 < 0.001 [4.08,8.94]
Antibody
 IgG1 to AMA1 1.08 0.004 [1.02,1.14]
 IgG1 to MSP1 1.08 0.001 [1.03,1.14]
 IgG1 to MSP2 3D7 1.09 0.001 [1.03,1.15]
 IgG1 to MSP2 FC27 1.06 0.032 [1.00,1.12]
 IgG1 to MSP3 1.13 0.002 [1.05,1.22]
 IgG1 to GLURP R0 1.07 0.052 [0.99,1.14]
 IgG1 to GLURP R2 1.07 0.028 [1.00,1.14]
 IgG3 to AMA1 1.09 0.002 [1.04,1.17]
 IgG3 to MSP1 1.06 0.020 [1.01,1.13]
 IgG3 to MSP2 3D7 1.05 0.026 [1.00,1.11]
 IgG3 to MSP2 FC27 1.05 0.038 [1.00,1.11]
 IgG3 to MSP3 1.10 0.007 [1.02,1.18]
 IgG3 to GLURP R0 1.01 0.667 [0.94,1.10]
 IgG3 to GLURP R2 1.07 0.018 [1.01,1.15]
Table 4 Association between  antibody levels and  the  risk 
of  malaria infection from  6 to  18  months of  age 
(multivariate analysis with logistic mixed model)
Significant p values (p < 0.05) are mentioned in italics
OR: odds ratio; OR > 1: variables associated with higher risk of malarial infection 
from 6 to 18 months of age; OR < 1: variables associated with lower risk of 
malarial infection from 6 to 18 months of age; p: p-value; CI: confidence interval
a 6, 9, 12 and 15 months quantifications were considered in analyses and 
6 month quantification was used as the age of reference
b Ethnic groups were Tori, Fon and other less represented ethnic groups (Aïzo, 
Yoruba, …). Tori was used as the reference group in the analyses
Variables OR p CI (95%)
IgG1 to AMA1 1.07 0.039 [1.00,1.15]
 Placental malaria 2.03 0.043 [1.02,4.06]
 Environmental risk 1.22 < 0.001 [1.16,1.29]
 Nutritional status 1.36 0.297 [0.76,2.46]
 Age (months)a
  9 1.97 0.004 [1.25,3.11]
  12 4.91 < 0.001 [3.08,7.81]
  15 6.90 < 0.001 [4.31,11.05]
 Ethnic  groupb
  Fon 0.96 0.926 [0.46,2.01]
  Others 0.51 0.037 [0.27,0.96]
IgG3 to AMA1 1.09 0.021 [1.01,1.18]
 Placental malaria 2.03 0.045 [1.01,4.07]
 Environmental risk 1.22 < 0.001 [1.16,1.29]
 Nutrition status 1.48 0.193 [0.81,2.69]
 Age (months)
  9 1.89 0.006 [1.20,2.99]
  12 5.10 < 0.001 [3.20,8.12]
  15 7.18 < 0.001 [4.49,11.50]
 Ethnic group
  Fon 0.90 0.790 [0.43,1.88]
  Others 0.49 0.031 [0.26,0.93]
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considering that protection could emerge only at the end 
of the follow-up. Cox proportional hazards regression 
model showed no association between Ab responses pre-
viously associated with asymptomatic infection clearance 
without anti-malarial treatment on the 15–18  months 
period (Fig.  1). Antibody titers quantified at 15  months 
of age were not associated with a modulation of parasite 
density in the following 3 months.
Discussion
After birth, infants exposed to repeat malaria infections 
gradually acquire anti-malarial antibodies while their 
maternal antibodies wane in time. Numerous antigens on 
the merozoite surface have been identified as important 
targets of naturally-acquired immunity, and the need to 
develop an effective blood-stage vaccine against P.  falci-
parum remains a research priority. In the present birth 
cohort study, unique in its multidisciplinary approach 
[34], its sample size and its closed follow-up, antibody 
responses to P. falciparum merozoite vaccine candidates 
were studied. The main objective of the present work was 
to evaluate whether cytophilic IgG acquired during the 
first 6- to 18-month period of life was sufficient to protect 
infants against P.  falciparum malaria. The key findings 
showed that (i) the level of cytophilic antibodies directed 
to AMA1 were associated with an increasing risk of 
malarial infection during the complete cohort follow-up and (ii) a group of infants with resolution of P. falciparum 
Table 5 Comparison of IgG levels in NCIG and CAIG
Multivariate analyses (linear mixed models) were performed to compare the difference of Ab mean level between both groups taking into account the Ab 
measurements at 6, 12, 15 and 18 months of age
Models were adjusted by age and environmental risk. Ab level from CAIG was considered as the reference in the model
Significant p values (p < 0.05) are mentioned in italics
Coef.: coefficient, Coef. > 0: indicate a higher level of Ab from 6 to 18 months of age in CAIG group compared to NCIG group, CI: confidence interval
a ERE represent environmental risk of exposure attributed quarterly for each infant included in the cohort
Comparison of IgG level in NCIG 
and CAIG
Age EREa
Coef. p CI 95% Coef. p CI 95% Coef. p CI 95%
IgG1 to AMA1 0.82 0.005 [0.25,1.40] 0.10 < 0.001 [0.06,0.15] 0.08 < 0.001 [0.04,0.13]
IgG1 to MSP1 0.47 0.129 [− 0.13,1.07] 0.11 < 0.001 [0.06,0.16] 0.15 < 0.001 [0.10,0.19]
IgG1 to MSP2 3D7 0.46 0.112 [− 0.11,1.04] 0.10 < 0.001 [0.05,0.15] 0.14 < 0.001 [0.09,0.18]
IgG1 to MSP2 FC27 0.59 0.042 [0.02,1.16] 0.09 < 0.001 [0.04,0.14] 0.12 < 0.001 [0.07,0.16]
IgG1 to MSP3 0.50 0.013 [0.10,0.91] 0.04 0.004 [0.01,0.07] 0.04 0.011 [0.009,0.07]
IgG1 to GLURP R0 0.20 0.361 [− 0.23,0.64] 0.02 0.177 [− 0.23,0.64] 0.024 0.154 [− 0.09,0.06]
IgG1 to GLURP R2 0.36 0.163 [− 0.14,0.86] 0.04 0.026 [0.005,0.08] 0.09 < 0.001 [0.05,0.13]
IgG3 to AMA1 0.78 0.003 [0.27,1.29] 0.09 < 0.001 [0.06,0.14] 0.11 < 0.001 [0.07,0.15]
IgG3 to MSP1 0.81 0.003 [0.27,1.36] 0.07 0.003 [0.02,0.12] 0.16 < 0.001 [0.11,0.20]
IgG3 to MSP2 3D7 0.57 0.067 [− 0.04,1.18] 0.15 < 0.001 [0.10,0.19] 0.11 < 0.001 [0.07,0.16]
IgG3 to MSP2 FC27 0.66 0.023 [0.09,1.24] 0.14 < 0.001 [0.09,0.19] 0.13 < 0.001 [0.08,0.17]
IgG3 to MSP3 0.64 0.002 [0.23,1.05] 0.05 0.002 [0.019,0.08] 0.07 < 0.001 [0.04,0.10]
IgG3 to GLURP R0 0.16 0.426 [− 0.23,0.55] 0.03 0.034 [0.002,0.06] 0.06 < 0.001 [0.03,0.09]
IgG3 to GLURP R2 0.53 0.021 [0.08,0.98] 0.06 0.003 [0.02,0.09] 0.10 < 0.001 [0.06,0.14]
Fig. 1 Hazard ratios and the 95% confidence interval of clinical 
malaria for IgG1 and IgG3 levels for children at 15 months. A 
Cox proportional hazards regression model was used to test the 
protective effect of IgG responses previously associated with the 
phenotype of asymptomatic infection clearance at 15 months of age 
in the whole sample (CAIG + NCIG). Hazards ratios obtained from 
Cox‑regression model adjusted by environmental risk of exposure 
to malaria, considering exposed children with no asymptomatic 
infection at the time of Ab measurement. The number of infants 
included in Cox‑regression model was 207 (13 infants had no Ab 
measurement at 15 months of age and 19 infants were excluded 
due to presence of asymptomatic infection at the time of Ab 
measurement). 66, 81, 50, 9 and 1 infants had, respectively, 0, 1, 2, 3 
and 4 malaria attacks between 15 and 18 months of follow‑up
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asymptomatic infections (CAIG) had higher cytophilic 
IgG levels to AMA1, MSP1, MSP2-FC27, GLURP-R2 and 
MSP3.
First result suggests that IgG1 and IgG3 responses to 
AMA1—quantified every 3 months in all infants of the 
cohort—represent more a biomarker of exposure than 
a biomarker of protection from malaria. Most of the 
results observed in other infant cohorts have revealed 
similar associations between the antibody level and an 
increased risk of malaria. In a cohort study conducted 
by Kusi in Ghana on infants between 1 and 5 years old, 
authors found that anti-AMA1 antibodies were asso-
ciated with a history of infection [45]. Stanisic et  al. 
investigated the role of antibodies to a panel of vaccine 
candidate antigens including AMA1 in cohorts of 1–4 
and 5–14  year-old children in Papua New Guinea and 
found that children with higher antibody levels had an 
increased risk of malaria compared to those with low 
or no detectable anti-malarial antibodies [31]. Another 
study conducted in Kenya showed that presence of 
detectable anti-malarial antibodies at 12  months of 
age was predictive of a higher risk of malaria in the 
subsequent year of life [46]. Kangoye et  al. found that 
antibodies to AMA1 and  MSP119 were significantly 
associated with an increasing malaria risk in two 
cohorts, each constituted by 40 children aged from 4 to 
6 weeks in Burkina Faso and Senegal [18]. Other studies 
that focused on acquired anti-malarial antibodies failed 
to show the protective role of these antibody responses 
against malaria attacks [13, 14]. The authors hypoth-
esized that antibody responses acquired by infants 
and young children through malaria exposure failed to 
reach a critical “protective” threshold until 4  years or 
older.
In order to better understand the acquisition of IgG 
to vaccine candidates leading to protection, a group of 
infants that experienced asymptomatic infections fol-
lowed by a disappearance of these asymptomatic infec-
tions during the follow-up (CAIG) was defined. CAIG 
definition was based on microscopic examination of 
TBS although the sensitivity of this method is question-
able. However, submicroscopic infections, even detect-
able by amplification of P. falciparum DNA could not be 
sufficient to prove the viability of the parasite as dem-
onstrated by different groups [47]. It could also not be 
exclude the possibility that some of these infants have 
taken a malaria treatment however it is unlikely for dif-
ferent reasons. First, these infections were asymptomatic. 
Secondly, the mothers were invited to bring their infants 
to the health centre for free care at any time in case of 
fever or clinical signs and the information concern-
ing malaria detection and its treatment were recorded. 
Finally, each child was visited every week by health 
workers at home during the entire follow-up to check his 
health status and collect information related to malaria. 
Based on this definition (i.e. including its limits), a sec-
ond result showed that higher levels of cytophilic IgG to 
AMA1, MSP1, MSP2-FC27, GLURP-R2 and MSP3 were 
observed in CAIG than in the control group composed of 
infants similarly exposed to malaria infection. These find-
ings suggest that a non-negligible proportion of infants 
(13%) seem to acquire a form of immunity associated 
with a control of asymptomatic malaria infection. These 
results also suggest that a certain quantity of specific IgG 
is needed to be able to control the infection. This result is 
in line with studies, which reported associations between 
anti-malarial protection and levels of antibodies directed 
to blood stage vaccine candidate antigens in young chil-
dren. Murungi et  al. found that anti-AMA1 antibodies 
were associated with a significant reduction in the odds 
of developing severe malaria in a unique prospective 
matched case–control study including Kenyan children 
aged 0 to 2 years [19]. Another study conducted by Nebie 
et  al. in children aged more than 6  months old in Bur-
kina Faso showed that IgG1 responses to AMA1 were 
associated with protection against malarial infection [12]. 
AMA1 is known for its high immunogenicity and this 
characteristic may explain why IgG to AMA1 is often 
found associated with the malaria status during infancy.
Antigenic variations are often reported and often 
alter the vaccine efficacy. Therefore, potential differ-
ences between the strains used to produce the recombi-
nant proteins and the Plasmodium strains circulating in 
this Beninese study area could lead to an underestima-
tion of antibody responses directed to antigen of inter-
est [48]. However, in this work, the objective was to 
study the IgG responses that were associated with pro-
tection to malaria and not the acquisition of the overall 
IgG response to all polymorphisms of an antigen. There-
fore, this study results also show that infant that were 
producing the highest levels of IgG to MSP3, MSP1 and 
MSP2 antigens were the ones that were controlling the 
best the infection. Numerous seroepidemiological stud-
ies have previously observed such associations in older 
individuals [10, 13, 14, 16]. It has been suggested that 
cytophilic antibodies directed to merozoite antigens are 
able to limit parasite development through direct inhibi-
tion of erythrocyte invasion by merozoites [49–51]. The 
functional attributes of IgG, using a standardized in vitro 
growth inhibition assay (GIA), were assessed in samples 
from 177 infants of this same cohort, but that study failed 
to show any association between the activity measured 
by GIA and anti-malarial protection [52]. The analysis 
of the same GIA data stratified with the groups CAIG/
NCIG showed a trend for higher GIA activity in the 
CAIG group (p = 0.11) suggesting a correlation between 
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quantity and quality of specific IgG response. The effect 
did not reach the significance probably due to the small 
number of samples with GIA data (NCIG, n = 64 out of 
183 and CAIG, n = 23 out of 53). Interestingly enough, 
this GIA was performed with purified IgG, meaning with 
no influence of the complement. First, this suggests that 
antibody-mediated complement pathway is not the only 
pathway giving protection and second the effect could be 
stronger and reach significance in presence of comple-
ment as suggested by others [53–55]. Moreover, as shown 
in some studies, antibodies to P. falciparum could trigger 
blood monocytes to control parasite density known as 
Antibody-Dependent Cellular Inhibition (ADCI) [56, 57] 
or antibodies to P.  falciparum merozoite surface protein 
1p19 could induce antibody-dependent respiratory burst 
(ADRB) in human neutrophils [58–60].
Conclusions
The findings presented here showed an association 
between high levels of cytophilic IgG responses to AMA1 
and an increased risk of malaria infection from 6 to 
18 months of life. Antibody acquisition to P. falciparum is 
highly dependent on parasite exposure and anti-malarial 
antibodies detected in plasma samples of the study pop-
ulation considered as a whole group represent rather a 
marker of exposure than a marker of protection. However 
the group of 53 asymptomatic infants who were able to 
control asymptomatic malaria infection presented higher 
antibody levels to AMA1, MSP1, MSP2-FC27, GLURP-
R2 and MSP3 than infants from the symptomatic group, 
underlying the possibility of a very early establishment of 
naturally acquire immunity against clinical malaria. This 
last result is encouraging in the context of the develop-
ment of multitarget P. falciparum vaccines.
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